MedTrace Logo

Study of Real-world Evidence With SGLT2i (Dapagliflozin) and DPP4i (Sitagliptin) in Type 2 Diabetes Patients in Spain

NCT04149067 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1080

Last updated 2019-11-04

No results posted yet for this study

Summary

The aim of this study is to develop a retrospective, multicenter and observational study in Spain in real clinical practice to assess the employment of dapagliflozin and to compare its effectiveness and safety with the data of sitagliptin, a DPP4 inhibitor. This is a widely used molecule in Spain with a large safety profile. It was chosen as a comparator because of the number of patients treated and because it is a real alternative at the time of making a decision about the treatment.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Dapagliflozin

Evaluation of the effectiveness and safety of the Dapagliflozin treatment.

DRUG

Sitagliptin

Evaluation of the effectiveness and safety of the Sitagliptin treatment.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

    lead OTHER

Principal Investigators

  • Cristobal Morales Portillo · Hospital Universitario Virgen Macarena

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-05
Primary Completion
2019-03-15
Completion
2019-03-15

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04149067 on ClinicalTrials.gov